The marketing authorisation for Altargo has been withdrawn at the request of the marketing authorisation holder.
Altargo : EPAR - Summary for the public (PDF/472.97 KB)
First published: 06/11/2007
Last updated: 15/03/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Glaxo Group Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
980 Great West Road
Middlesex TW8 9GS
09/11/2015 Altargo - EMEA/H/C/000757 - N/0030
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antibiotics and chemotherapeutics for dermatological use
Short term treatment of the following superficial skin infections:
- infected small lacerations, abrasions or sutured wounds.
See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.